Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.58 |
| ▸ | HTR2A | P28223 | 12/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly2624803 SCHEMBL379812 | 0.88 | HTR2C (0.73) | HTR2CHTR2AHRH1DRD2 | |
| Ly2624803 SCHEMBL31208381 | 0.88 | HTR2C (0.73) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL23242554 | 0.87 | HTR2A (0.69) | HTR2CHTR2AHRH1 | |
| SCHEMBL23242508 | 0.85 | HTR2C (0.81) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194104 | 0.85 | HTR2C (0.55) | HTR2CHTR2AHRH4HRH1DRD2 | |
| SCHEMBL23242618 | 0.85 | HTR2A (0.80) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL23242517 | 0.83 | HTR2A (0.79) | HTR2CHTR2AHRH4HRH1DRD2 | |
| SCHEMBL23242562 | 0.83 | HTR2A (0.81) | HTR2CHTR2AHRH4HRH1 | |
| SCHEMBL10194090 | 0.82 | HTR2A (0.79) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194094 | 0.81 | HTR2A (0.87) | HTR2CHTR2AHRH4HRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804804-B1 | 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS | HYPNION INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | HTR2C 4/4885HTR2A 9/4885HRH4 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.